Slide 1: neffy – the transformative needle-free solution for severe allergic reactions
NASDAQ: SPRY neffy – the transformative needle-free solution for severe allergic reactions August 2025
Slide 2: Forward-looking statements
Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements reg
Slide 3: Transforming the Emergency Treatment of Type I Allergic Reactions
Transforming the Emergency Treatment of Type I Allergic Reactions • neffy®: first and only FDA approved “no needle, no injection” solution for the emergency treatment of Type I allergic reactions for those 4 years and older who weigh 33 lbs or more (2 mg and 1 mg now available) • Strong execution ($
Slide 4: Anaphylaxis is Accompanied by Many Frequent Symptoms
Anaphylaxis is Accompanied by Many Frequent Symptoms Symptoms (>2%) reported during US anaphylaxis events 2-14 Common Anaphylaxis Symptoms Include: 0% 20% 40% 60% 80% 100% Urticaria or Angioedema >85% urticaria (hives, erythema) or angioedema Urticaria Flushing Mucosal (swelling of the face, lips, t
Slide 5: Type I Allergy Patients Face Significant Limitations with Other Treatment Options that neffy may help to address
Type I Allergy Patients Face Significant Limitations with Other Treatment Options that neffy may help to address NO TREATMENT REFUSAL OF DELAY IN USER ERROR IN PROBLEM: READILY AVAILABLE TREATMENT TREATMENT TREATMENT ARS Pharmaceuticals, Inc. Investor Presentation – August 2025 ONLY 10% - 20% of pat
Slide 6: Addressing the Significant Unmet Needs in US Severe Allergic Reaction Patient Population
Addressing the Significant Unmet Needs in US Severe Allergic Reaction Patient Population Epidemiology prevalence data estimates Consistent Market Growth (Units) +6.5% CAGR since 2010, +12.7% YoY in 20231 ~40M patients with type 1 allergic reactions2-9 ARS Pharmaceuticals, Inc. Investor Presentation
Slide 7: Ex-US partners enable ARS to focus exclusively on the United States
Ex-US partners enable ARS to focus exclusively on the United States ARS has received FDA/EC/MHRA approval, and filed in Canada, China, and AUS/NZ within 6 months of FDA approval; these regions represent 98% of global epinephrine autoinjector sales1 ARS Pharmaceuticals, Inc. Investor Presentation – A
Slide 8: Commercialization Progress
ARS Pharmaceuticals, Inc. Investor Presentation – August 2025 Commercialization Progress
Slide 9: neffy Strategic Objectives for Commercialization
neffy Strategic Objectives for Commercialization Ongoing 2025 Mid to late 2025 ARS Pharmaceuticals, Inc. Investor Presentation – August 2025 Launch of 2 mg neffy EDUCATE PRESCRIBERS ACTIVATE PATIENTS (Sept 23, 2024) Drive adoption within DTC campaign launched in two specialty and high phases – first
Slide 10: Strong demand to learn about neffy among HCPs targeted to date by ARS efforts
Strong demand to learn about neffy among HCPs targeted EDUCATE to date by ARS efforts >9,700 HCPs have prescribed neffy to date, >2,800 HCPs have enrolled in the neffy with 70% of prescriptions submitted by the Experience Program ARS Pharmaceuticals, Inc. Investor Presentation – August 2025 priority
Slide 11: Healthcare Providers Indicate Significant Uptake in 2025
Healthcare Providers Indicate Significant Uptake in 2025 Top 3 neffy barriers to becoming the treatment of choice for healthcare providers (HCPs) Results of March 2025 HCP research, n = 250 (December 2024 HCP research, n = 150) ~2 of 3 ~9 of 10 ARS Pharmaceuticals, Inc. Investor Presentation – Augus
Slide 12: On track to ensuring broad neffy access for patients
On track to ensuring broad neffy access for patients FACILITATE Payers recognize the value of neffy Dispensing by major PBM for neffy is consistent with the total epinephrine market, due to neffy Rx approval rates ARS Pharmaceuticals, Inc. Investor Presentation – August 2025 List price for two doses
Slide 13: Consumer awareness is the key to neffy uptake and creates the opportunity for significant growth over the summer
Consumer awareness is the key to neffy uptake and creates ACTIVATE the opportunity for significant growth over the summer Results of the March/April 2025 Consumer Market Research Study (n = 400 patients) Before Direct-to-Consumer Campaign Launch (May 15, 2025) ARS Pharmaceuticals, Inc. Investor Pres
Slide 14: ‘Hello neffy, Goodbye Needles’ DTC campaign and jingle launched in May 2025
‘Hello neffy, Goodbye Needles’ DTC campaign and jingle ACTIVATE launched in May 2025 prior to peak back to school season ARS Pharmaceuticals, Inc. Investor Presentation – August 2025 ‘Hello, neffy! Hello, neffy! No needles Goodbye!’ Expansive consumer marketing campaign: ~$50 million in 2025 DTC sp
Slide 15: Robust increase in consumer awareness in only the first two months of the DTC campaign
Robust increase in consumer awareness in only the first ACTIVATE two months of the DTC campaign Impact on aided consumer ARS Pharmaceuticals, Inc. Investor Presentation – August 2025 awareness of neffy (%) ~1 billion Impressions of neffy across integrated multimedia channels ~5M Views in YouTube via
Slide 16: Multiple tailwinds going into “back to school” peak season (Q3 2025) set up neffy for an important sales inflection point
Multiple tailwinds going into “back to school” peak season (Q3 2025) set up neffy for an important sales inflection point neffy “Back to school” tailwinds “Back to school” seasonality trends 1. Availability of 1 mg dose in May 2025 covers children down to 4 years of age ARS Pharmaceuticals, Inc. Inv
Slide 17: Treatment of acute flares in chronic spontaneous urticaria patients on antihistamines represents blockbuster opportunity
Treatment of acute flares in chronic spontaneous urticaria patients on antihistamines represents blockbuster opportunity neffy Shows Robust and Rapid Clinical Responses in ~2M diagnosed chronic urticaria patients Treatment-Resistant Chronic Spontaneous Urticaria (CSU) based on 12 month US prevalence
Slide 18: A Path to Blockbuster Potential for neffy
A Path to Blockbuster Potential for neffy 1 mg launch in May 2025 2 mg launch (15 to <30 kg) 2026 Multi-blockbuster (30 kg+) Intensifying Growth peak sales potential 2025 ARS Pharmaceuticals, Inc. Investor Presentation – August 2025 driven by initial $3B segment, • Continued investment into ~$7B exp